CA2239976A1 - Chimiotherapie par oligonucleotides antisens de l'hypertrophie ou du cancer de la prostate - Google Patents

Chimiotherapie par oligonucleotides antisens de l'hypertrophie ou du cancer de la prostate Download PDF

Info

Publication number
CA2239976A1
CA2239976A1 CA 2239976 CA2239976A CA2239976A1 CA 2239976 A1 CA2239976 A1 CA 2239976A1 CA 2239976 CA2239976 CA 2239976 CA 2239976 A CA2239976 A CA 2239976A CA 2239976 A1 CA2239976 A1 CA 2239976A1
Authority
CA
Canada
Prior art keywords
oligonucleotides
seq
oligonucleotide
gene
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2239976
Other languages
English (en)
Inventor
Paul A. Zamecnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Worcester Foundation for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Worcester Foundation for Biomedical Research filed Critical Worcester Foundation for Biomedical Research
Publication of CA2239976A1 publication Critical patent/CA2239976A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur un procédé inhibant sélectivement la croissance des cellules prostatiques ou les tuant à l'aide d'oligonucléotides antisens de gènes spécifiques de la prostate. Lesdits oligonucléotides peuvent présenter des structures d'acides nucléiques naturels ou peuvent être des oligonucléotides modifiés à stabilité renforcée ou ciblant des tissus spécifiques. Les gènes spécifiques de la prostate vers lesquels les antisens peuvent être dirigés comportent les gènes AR et .alpha.FGF. L'invention porte également sur des préparations pharmaceutiques comprenant lesdits oligonucléotides antisens utilisées dans ces procédés. Lesdits procédés et produits s'avèrent notamment utiles pour le traitement de l'hypertrophie et du cancer de la prostate.
CA 2239976 1995-09-20 1996-09-20 Chimiotherapie par oligonucleotides antisens de l'hypertrophie ou du cancer de la prostate Abandoned CA2239976A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US401895P 1995-09-20 1995-09-20
US60/004,018 1995-09-20

Publications (1)

Publication Number Publication Date
CA2239976A1 true CA2239976A1 (fr) 1997-03-27

Family

ID=21708727

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2239976 Abandoned CA2239976A1 (fr) 1995-09-20 1996-09-20 Chimiotherapie par oligonucleotides antisens de l'hypertrophie ou du cancer de la prostate

Country Status (4)

Country Link
EP (1) EP0851919A1 (fr)
AU (1) AU7366296A (fr)
CA (1) CA2239976A1 (fr)
WO (1) WO1997011170A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CN101818145A (zh) 1998-03-20 2010-09-01 联邦科学和工业研究组织 控制基因表达
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
CN1213057C (zh) * 1998-11-09 2005-08-03 中国人民解放军军事医学科学院放射医学研究所 抑制端粒酶活性反义寡核苷酸结构及用途
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
DK2796553T3 (da) 2000-03-30 2019-09-30 Whitehead Inst Biomedical Res Rna-sekvensspecifikke formidlere af rna-interferens
ES2728168T3 (es) * 2000-12-01 2019-10-22 Max Planck Gesellschaft Moléculas pequeñas de ARN que median en la interferencia de ARN
EP1229134A3 (fr) 2001-01-31 2004-01-28 Nucleonics, Inc Utilisation de l'inhibition post-transcriptionnelle pour l'identification des séquences d'acides nucléiques qui modifient la fonction d'une cellule
WO2004014933A1 (fr) 2002-08-07 2004-02-19 University Of Massachusetts Compositions pour l'interference de l'arn et procedes d'utilisation
AR041407A1 (es) * 2003-09-26 2005-05-18 Nestor Alberto Kerner Oligonucleotidos antiandrogenos utilizables en el tratamiento de patologias dermatologicas relacionadas con el metabolismo de los androgenos, sus composiciones farmaceuticas y sus usos y metodos de tratamiento
WO2007041497A2 (fr) * 2005-09-30 2007-04-12 Cleveland Biolabs, Inc. Modulation du recepteur d'androgene
US7737125B2 (en) 2007-11-26 2010-06-15 Enzon Pharamaceuticals, Inc. LNA antagonists targeting the androgen receptor
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
EP2646553A4 (fr) 2010-11-12 2015-01-07 Santaris Pharma As Compositions et procédés pour le traitement de troubles dépendant des récepteurs androgènes y compris les cancers
AR092982A1 (es) 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
JP2016516005A (ja) 2013-02-25 2016-06-02 ノバルティス アーゲー 新規のアンドロゲンレセプター変異
RU2016104927A (ru) * 2013-11-01 2017-12-06 Эверон Байосайенсис, Инк. Молекулярные мишени для селективного уничтожения сенесцентных клеток

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307030B1 (en) * 1988-04-15 2001-10-23 The University Of North Carolina At Chapel Hill Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions
AU4846793A (en) * 1992-09-04 1994-03-29 Baylor College Of Medicine Novel triplex forming oligonucleotides and methods for their use
AU7983294A (en) * 1993-10-19 1995-05-08 Regents Of The University Of Michigan, The P53-mediated apoptosis
US5556956A (en) * 1993-11-04 1996-09-17 Board Of Regents, The University Of Texas System Methods and compositions relating to the androgen receptor gene and uses thereof
US6468981B1 (en) * 1994-07-29 2002-10-22 Emory University Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors

Also Published As

Publication number Publication date
WO1997011170A1 (fr) 1997-03-27
EP0851919A1 (fr) 1998-07-08
AU7366296A (en) 1997-04-09

Similar Documents

Publication Publication Date Title
US7420050B2 (en) TGF-β-specific covalently closed antisense molecule
CA2239976A1 (fr) Chimiotherapie par oligonucleotides antisens de l'hypertrophie ou du cancer de la prostate
US5783683A (en) Antisense oligonucleotides which reduce expression of the FGFRI gene
US5734039A (en) Antisense oligonucleotides targeting cooperating oncogenes
FI112379B (fi) Menetelmä terapeuttisesti käyttökelpoisten oligonukleotidien valmistamiseksi
US5652222A (en) Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides
SK3652003A3 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
JP2023158214A (ja) Ｈｉｆ２αの遺伝子発現を阻害する組成物及び方法
WO2011046983A2 (fr) Procédés et compositions de modulation de l'expression génique en utilisant des médicaments à base d'oligonucléotides administrés in vivo ou in vitro
WO1991018625A1 (fr) Inversion a mediation ribozymique de transformation par clivage de l'arn oncogene hras
EP1144609B1 (fr) Oligonucleotides chimeres antisens et formulations de transfection cellulaire
CA2105595A1 (fr) Polynucleotides antisens
JPH10502820A (ja) 腫瘍増殖、浸潤および転移を阻害するためのオリゴヌクレオシド化合物および方法
EP0668782B1 (fr) Combinaison d'un agent anti-neoplasique et d'oligonucleotides antisens dans le traitement du cancer
Rubenstein et al. Antisense oligonucleotide intralesional therapy for human PC‐3 prostate tumors carried in athymic nude mice
JPH11512601A (ja) 修飾プロテインキナーゼａ特異的オリゴヌクレオチドおよびその使用法
WO1995024223A1 (fr) Inhibition de la proliferation cellulaire par des oligonucleotides non codants specifiques contre e2f-1
EP1071764B1 (fr) Oligonucleotides antisens destines a inhiber l'expression d'une sous-unite de l'integrine alphav
CA2223109A1 (fr) Utilisation d'oligonucleotides antisens complementaires de l'arnm du recepteur de l'interleukine-6 pour inhiber la proliferation cellulaire
CA2232390A1 (fr) Chimiotherapie par les oligonucleotides antisens de l'hyperplasie ou du cancer de la prostate
WO1998013072A1 (fr) Compositions et procedes destines au traitement de la resistance multiple aux anticancereux
CA2446606A1 (fr) Inhibiteurs des isoformes de methyltransferase d'adn
WO1998049287A2 (fr) Oligonucleotides antisens specifiques d'une thymidylate synthase
US20030176384A1 (en) Antisense oligonucleotides for the inhibition of integrin alphav -subunit expression
US20050032714A1 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Legal Events

Date Code Title Description
FZDE Dead